Literature DB >> 33768448

Stent-free duct-to-duct biliary reconstruction after hepatectomy for liver tumors involving biliary confluence at the hepatic hilum: a monocentric experience.

Daniele Del Fabbro1, Matteo Maria Cimino1, Fabio Procopio1, Guido Torzilli2,3.   

Abstract

Roux-en-Y hepaticojejunostomy (HJ) is the standard of care for biliary reconstruction. Its weaknesses are the loss of the sphincter functionality, which could lead to repeated cholangitis, and the reduced endoscopic accessibility to the biliary tree. In the context of liver transplantation it has been shown that duct-to-duct biliary anastomosis may be suitable as an alternative to HJ, significantly reducing the risk of cholangitis. Here we present our experience on stent-free duct-to-duct reconstruction, performed in six patients receiving hepatectomy with resection of the biliary confluence. Operative mortality was nil. Anastomotic leak occurred in four patients and resolved spontaneously in all cases. One patient developed anastomotic stricture 17 months after surgery and only one patient developed tumor recurrence at the anastomotic site; in both cases the endoscopic stenting succeeded in restoring the ducts patency. With a median follow-up of 24 months (range 19-28 months), no cholangitis or other biliary-related complications were observed. Our experience, although limited, shows satisfactory oncological and functional outcomes, confirming all previously published results.

Entities:  

Keywords:  Biliary anastomosis; Biliary resection; Liver resection; Liver tumors

Year:  2021        PMID: 33768448     DOI: 10.1007/s13304-021-00987-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  1 in total

Review 1.  T-Tube or no T-tube in the reconstruction of the biliary tract during orthotopic liver transplantation: systematic review and meta-analysis.

Authors:  Carina Riediger; Michael W Müller; Christoph W Michalski; Norbert Hüser; Tibor Schuster; Jörg Kleeff; Helmut Friess
Journal:  Liver Transpl       Date:  2010-06       Impact factor: 5.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.